Tenax Therapeutics, INC Schedule 13G passive stakes

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G, reporting beneficial ownership of 1,080,700 shares, representing 2.9% of Tenax Therapeutics, Inc.'s common stock.

Venrock Healthcare Capital Partners III, L.P. and affiliated entities report a beneficial ownership of 4.7% of Tenax Therapeutics, Inc. common stock, primarily through warrants.

Biotechnology Value Fund and associated entities have disclosed a significant beneficial ownership stake of 9.99% in Tenax Therapeutics, Inc., primarily through pre-funded warrants and warrants.

RTW Investments, LP and Roderick Wong report beneficial ownership of 2,866,654 shares, representing 9.9% of Tenax Therapeutics, Inc.'s common stock, as of June 30, 2026.

Adage Capital Management, L.P. and associated entities have amended their Schedule 13G filing to report beneficial ownership of 6.81% of Tenax Therapeutics, Inc. common stock.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported a 3.3% stake in Tenax Therapeutics, Inc.

T. Rowe Price Associates, Inc. filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.2% in Tenax Therapeutics, Inc.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in Tenax Therapeutics, Inc.

Logos Global Management LP and affiliated entities have filed a Schedule 13G reporting a 3% beneficial ownership stake in Tenax Therapeutics, Inc.

Stonepine Capital Management, LLC and associated entities have filed a Schedule 13G reporting a 3.7% beneficial ownership stake in Tenax Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates have reported a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc. as of March 31, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 3.1% beneficial ownership stake in Tenax Therapeutics, Inc. as of March 31, 2026.

Lind Global Fund II LP and affiliates disclosed a 0.78% beneficial ownership stake in Tenax Therapeutics, Inc. via warrants.

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in Tenax Therapeutics, Inc. via Schedule 13G filing.

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have collectively reported beneficial ownership of 2.3% of Tenax Therapeutics' common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 1,867,630 shares, representing 9.9% of Tenax Therapeutics, Inc. common stock.

Millennium Management and affiliated entities report a 2.1% beneficial ownership stake in Tenax Therapeutics, Inc.

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 11.0% in Tenax Therapeutics Inc., holding 2,841,114 shares of common stock as of April 30, 2026.

T. Rowe Price Associates, Inc. has reported a significant beneficial ownership stake of 17.2% in Tenax Therapeutics Inc., holding 2,951,116 shares of common stock as of March 31, 2026.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 2.1% of Tenax Therapeutics, Inc. common stock as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G amendment indicating they no longer beneficially own more than five percent of Tenax Therapeutics, Inc. common stock.

Ikarian Capital, LLC and Neil Shahrestani have reported a beneficial ownership of 6.7% in Tenax Therapeutics, Inc. as of March 31, 2026.

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have disclosed beneficial ownership stakes of up to 6.4% in Tenax Therapeutics, Inc.

RTW Investments and Roderick Wong disclose a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc., as detailed in an amended Schedule 13G filing.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 9.6% of Tenax Therapeutics, Inc.'s common stock.

Perceptive Advisors LLC and affiliates reported a 7.0% passive ownership stake in Tenax Therapeutics, Inc., holding 439,142 shares of common stock.

Janus Henderson Group plc has reported a 9.99% passive beneficial ownership stake in Tenax Therapeutics, Inc., totaling 623,733 shares.

Ikarian Capital and Neil Shahrestani have reported a 15.5% beneficial ownership stake in Tenax Therapeutics, holding 967,600 shares.

A group of Venrock entities and individuals have disclosed a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc. common stock.

Lind Global Fund II LP, along with its general partner and managing member, reported beneficial ownership of 8.8% of Tenax Therapeutics, Inc. common stock through warrants.